NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives $49.42 Consensus PT from Brokerages

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has received an average recommendation of “Moderate Buy” from the fourteen research firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $49.4167.

A number of equities research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Jefferies Financial Group restated a “buy” rating and set a $45.00 target price on shares of NewAmsterdam Pharma in a report on Monday, July 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Friday, July 17th. Royal Bank Of Canada boosted their price target on NewAmsterdam Pharma from $47.00 to $51.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 30th. Finally, BMO Capital Markets began coverage on NewAmsterdam Pharma in a research note on Monday, July 20th. They set an “outperform” rating and a $58.00 price target for the company.

NewAmsterdam Pharma Stock Performance

Shares of NAMS opened at $28.46 on Friday. The firm has a market cap of $3.33 billion, a PE ratio of -15.90 and a beta of 0.08. The firm’s 50 day moving average price is $32.31 and its 200 day moving average price is $32.69. NewAmsterdam Pharma has a twelve month low of $21.14 and a twelve month high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. The business had revenue of $3.04 million during the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%. On average, sell-side analysts anticipate that NewAmsterdam Pharma will post -1.78 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CAO Louise Frederika Kooij sold 105,000 shares of the business’s stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $30.34, for a total value of $3,185,700.00. Following the completion of the sale, the chief accounting officer directly owned 24,353 shares in the company, valued at approximately $738,870.02. The trade was a 81.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last three months, insiders sold 210,000 shares of company stock valued at $6,713,550. 12.74% of the stock is currently owned by insiders.

Hedge Funds Weigh In On NewAmsterdam Pharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Frazier Life Sciences Management L.P. lifted its stake in shares of NewAmsterdam Pharma by 1.4% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 16,943,774 shares of the company’s stock worth $594,388,000 after buying an additional 241,818 shares during the last quarter. Capital World Investors grew its stake in NewAmsterdam Pharma by 1.6% in the 4th quarter. Capital World Investors now owns 9,984,000 shares of the company’s stock valued at $350,239,000 after buying an additional 161,289 shares during the last quarter. Wellington Management Group LLP grew its stake in NewAmsterdam Pharma by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock valued at $114,332,000 after buying an additional 697,129 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in NewAmsterdam Pharma by 54.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock worth $54,566,000 after acquiring an additional 1,062,359 shares during the period. Finally, Polar Capital Holdings Plc raised its holdings in NewAmsterdam Pharma by 15.6% in the 3rd quarter. Polar Capital Holdings Plc now owns 2,911,634 shares of the company’s stock worth $82,807,000 after acquiring an additional 393,855 shares during the period. Institutional investors and hedge funds own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.